Trientine - Protemix

Drug Profile

Trientine - Protemix

Alternative Names: GC 811007; Laszarin; PX 811019

Latest Information Update: 28 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Protemix Corporation
  • Class Ethylenediamines; Small molecules
  • Mechanism of Action Chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Type 2 diabetes mellitus
  • Discontinued Diabetic cardiomyopathy

Most Recent Events

  • 20 Jun 2016 Protemix Corporation completes a phase II trial in Non-diabetic Subjects and Type 2 Diabetes Mellitus in New Zealand before February 24, 2012 (ACTRN12612000261819)
  • 24 Feb 2012 Phase-II clinical trials in Type-2 diabetes mellitus in New Zealand (PO)
  • 30 Jun 2010 Discontinued - Phase-II for Diabetic cardiomyopathy in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top